{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T18:40:53Z","timestamp":1704480053369},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Henan Provincial Science and Technology Research Program Joint Co-construction Project","award":["2018020256"],"award-info":[{"award-number":["2018020256"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cuproptosis, a newly discovered mode of cell death, has been less studied in hepatocellular carcinoma (HCC). Exploring the molecular characteristics of different subtypes of HCC based on cuproptosis-related genes (CRGs) is meaningful to HCC. In addition, immunotherapy plays a pivotal role in treating HCC. Exploring the sensitivity of immunotherapy and building predictive models are critical for HCC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The 357 HCC samples from the TCGA database were classified into three subtypes, Cluster 1, Cluster 2, and Cluster 3, based on the expression levels of ten CRGs genes using consensus clustering. Six machine learning algorithms were used to build models that identified the three subtypes. The molecular features of the three subtypes were analyzed and compared from some perspectives. Moreover, based on the differentially expressed genes (DEGs) between Cluster 1 and Cluster 3, a prognostic scoring model was constructed using LASSO regression and Cox regression, and the scoring model was used to predict the efficacy of immunotherapy in the IMvigor210 cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Cluster 3 had the worst overall survival compared to Cluster 1 and Cluster 2 (<jats:italic>P<\/jats:italic>\u2009=\u20090.0048). The AUC of the Catboost model used to identify Cluster 3 was 0.959. Cluster 3 was significantly different from the other two subtypes in gene mutation, tumor mutation burden, tumor microenvironment, the expression of immune checkpoint inhibitor genes and <jats:italic>N<\/jats:italic><jats:sup>6<\/jats:sup>-methyladenosine regulatory genes, and the sensitivity to sorafenib. We believe Cluster 3 is more sensitive to immunotherapy from the above analysis results. Therefore, based on the DEGs between Cluster 1 and Cluster 3, we obtained a 7-gene scoring prognostic model, which achieved meaningful results in predicting immunotherapy efficacy in the IMvigor210 cohort (<jats:italic>P<\/jats:italic>\u2009=\u20090.013).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study provides new ideas for molecular characterization and immunotherapy of HCC from machine learning and bioinformatics. Moreover, we successfully constructed a prognostic model of immunotherapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12859-022-04997-0","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T10:08:49Z","timestamp":1668593329000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Identification of the cuproptosis-related molecular subtypes and an immunotherapy prognostic model in hepatocellular carcinoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Li","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiufeng","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongqiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueyuan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanwei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"issue":"1","key":"4997_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"20","key":"4997_CR2","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"6","key":"4997_CR3","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.molonc.2015.02.007","volume":"9","author":"JL Allensworth","year":"2015","unstructured":"Allensworth JL, Evans MK, Bertucci F, Aldrich AJ, Festa RA, Finetti P, et al. Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer. Mol Oncol. 2015;9(6):1155\u201368.","journal-title":"Mol Oncol"},{"issue":"6","key":"4997_CR4","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.drudis.2020.04.003","volume":"25","author":"H Li","year":"2020","unstructured":"Li H, Wang J, Wu C, Wang L, Chen ZS, Cui W. The combination of disulfiram and copper for cancer treatment. Drug Discov Today. 2020;25(6):1099\u2013108.","journal-title":"Drug Discov Today"},{"key":"4997_CR5","doi-asserted-by":"publisher","first-page":"110048","DOI":"10.1016\/j.biopha.2020.110048","volume":"126","author":"Y Xu","year":"2020","unstructured":"Xu Y, Zhou Q, Feng X, Dai Y, Jiang Y, Jiang W, et al. Disulfiram\/copper markedly induced myeloma cell apoptosis through activation of JNK and intrinsic and extrinsic apoptosis pathways. Biomed Pharmacother. 2020;126:110048.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"4997_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41568-021-00417-2","volume":"22","author":"EJ Ge","year":"2022","unstructured":"Ge EJ, Bush AI, Casini A, Cobine PA, Cross JR, DeNicola GM, et al. Connecting copper and cancer: from transition metal signalling to metalloplasia. Nat Rev Cancer. 2022;22(2):102\u201313.","journal-title":"Nat Rev Cancer"},{"issue":"19","key":"4997_CR7","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1158\/0008-5472.CAN-20-0471","volume":"80","author":"F Voli","year":"2020","unstructured":"Voli F, Valli E, Lerra L, Kimpton K, Saletta F, Giorgi FM, et al. Intratumoral copper modulates PD-L1 expression and influences tumor immune evasion. Cancer Res. 2020;80(19):4129\u201344.","journal-title":"Cancer Res"},{"issue":"6586","key":"4997_CR8","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","volume":"375","author":"P Tsvetkov","year":"2022","unstructured":"Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375(6586):1254\u201361.","journal-title":"Science"},{"key":"4997_CR9","doi-asserted-by":"publisher","first-page":"925618","DOI":"10.3389\/fimmu.2022.925618","volume":"13","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Zeng X, Wu Y, Liu Y, Zhang X, Song Z. Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in hepatocellular carcinoma. Front Immunol. 2022;13:925618.","journal-title":"Front Immunol"},{"key":"4997_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btab647","author":"G Pio","year":"2021","unstructured":"Pio G, Mignone P, Magazzu G, Zampieri G, Ceci M, Angione C. Integrating genome-scale metabolic modelling and transfer learning for human gene regulatory network reconstruction. Bioinformatics. 2021. https:\/\/doi.org\/10.1093\/bioinformatics\/btab647.","journal-title":"Bioinformatics"},{"key":"4997_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaa427","author":"J Gong","year":"2021","unstructured":"Gong J, Li R, Chen Y, Zhuo Z, Chen S, Cao J, et al. HCC subtypes based on the activity changes of immunologic and hallmark gene sets in tumor and nontumor tissues. Brief Bioinform. 2021. https:\/\/doi.org\/10.1093\/bib\/bbaa427.","journal-title":"Brief Bioinform"},{"issue":"3","key":"4997_CR12","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.gpb.2021.03.008","volume":"19","author":"L Wu","year":"2021","unstructured":"Wu L, Jiang M, Wang Y, Zhou B, Sun Y, Zhou K, et al. scDPN for high-throughput single-cell CNV detection to uncover clonal evolution during HCC recurrence. Genom Proteom Bioinform. 2021;19(3):346\u201357.","journal-title":"Genom Proteom Bioinform"},{"issue":"6","key":"4997_CR13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman MJ, Craft B, Hastie M, Repecka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675\u20138.","journal-title":"Nat Biotechnol"},{"issue":"12","key":"4997_CR14","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1093\/annonc\/mdx518","volume":"28","author":"A Necchi","year":"2017","unstructured":"Necchi A, Joseph RW, Loriot Y, Hoffman-Censits J, Perez-Gracia JL, Petrylak DP, et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. Ann Oncol. 2017;28(12):3044\u201350.","journal-title":"Ann Oncol"},{"issue":"12","key":"4997_CR15","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572\u20133.","journal-title":"Bioinformatics"},{"issue":"11","key":"4997_CR16","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747\u201356.","journal-title":"Genome Res"},{"issue":"1","key":"4997_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.","journal-title":"Genome Med"},{"issue":"W1","key":"4997_CR18","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509\u201314.","journal-title":"Nucleic Acids Res"},{"key":"4997_CR19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","volume":"1711","author":"B Chen","year":"2018","unstructured":"Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243\u201359.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"4997_CR20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12943-019-1109-9","volume":"18","author":"L He","year":"2019","unstructured":"He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18(1):176.","journal-title":"Mol Cancer"},{"issue":"1","key":"4997_CR21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12943-020-01204-7","volume":"19","author":"T Wang","year":"2020","unstructured":"Wang T, Kong S, Tao M, Ju S. The potential role of RNA N6-methyladenosine in cancer progression. Mol Cancer. 2020;19(1):88.","journal-title":"Mol Cancer"},{"issue":"6","key":"4997_CR22","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/apt.14913","volume":"48","author":"M Pinter","year":"2018","unstructured":"Pinter M, Peck-Radosavljevic M. Review article: systemic treatment of hepatocellular carcinoma. Aliment Pharmacol Ther. 2018;48(6):598\u2013609.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"4997_CR23","doi-asserted-by":"publisher","first-page":"e107468","DOI":"10.1371\/journal.pone.0107468","volume":"9","author":"P Geeleher","year":"2014","unstructured":"Geeleher P, Cox N, Huang RS. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE. 2014;9(9):e107468.","journal-title":"PLoS ONE"},{"key":"4997_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7.","journal-title":"BMC Bioinform"},{"issue":"12","key":"4997_CR25","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.","journal-title":"Genome Biol"},{"issue":"1","key":"4997_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"J Friedman","year":"2010","unstructured":"Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1\u201322.","journal-title":"J Stat Softw"},{"key":"4997_CR27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jclinepi.2015.12.005","volume":"74","author":"B Van Calster","year":"2016","unstructured":"Van Calster B, Nieboer D, Vergouwe Y, De Cock B, Pencina MJ, Steyerberg EW. A calibration hierarchy for risk models was defined: from utopia to empirical data. J Clin Epidemiol. 2016;74:167\u201376.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"4997_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12874-017-0332-6","volume":"17","author":"AN Kamarudin","year":"2017","unstructured":"Kamarudin AN, Cox T, Kolamunnage-Dona R. Time-dependent ROC curve analysis in medical research: current methods and applications. BMC Med Res Methodol. 2017;17(1):53.","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"4997_CR29","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.eururo.2018.08.038","volume":"74","author":"B Van Calster","year":"2018","unstructured":"Van Calster B, Wynants L, Verbeek JFM, Verbakel JY, Christodoulou E, Vickers AJ, et al. Reporting and interpreting decision curve analysis: a guide for investigators. Eur Urol. 2018;74(6):796\u2013804.","journal-title":"Eur Urol"},{"issue":"D1","key":"4997_CR30","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607\u201313.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"4997_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"4997_CR32","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00401-020-02188-w","volume":"140","author":"P Sievers","year":"2020","unstructured":"Sievers P, Hielscher T, Schrimpf D, Stichel D, Reuss DE, Berghoff AS, et al. CDKN2A\/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathol. 2020;140(3):409\u201313.","journal-title":"Acta Neuropathol"},{"issue":"12","key":"4997_CR33","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1038\/bjc.2013.251","volume":"108","author":"X Xing","year":"2013","unstructured":"Xing X, Cai W, Shi H, Wang Y, Li M, Jiao J, et al. The prognostic value of CDKN2A hypermethylation in colorectal cancer: a meta-analysis. Br J Cancer. 2013;108(12):2542\u20138.","journal-title":"Br J Cancer"},{"issue":"21","key":"4997_CR34","first-page":"4868","volume":"57","author":"M Castellano","year":"1997","unstructured":"Castellano M, Pollock PM, Walters MK, Sparrow LE, Down LM, Gabrielli BG, et al. CDKN2A\/p16 is inactivated in most melanoma cell lines. Cancer Res. 1997;57(21):4868\u201375.","journal-title":"Cancer Res"},{"issue":"15","key":"4997_CR35","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1056\/NEJMoa1806627","volume":"380","author":"ABP van Kuilenburg","year":"2019","unstructured":"van Kuilenburg ABP, Tarailo-Graovac M, Richmond PA, Drogemoller BI, Pouladi MA, Leen R, et al. Glutaminase deficiency caused by short tandem repeat expansion in GLS. N Engl J Med. 2019;380(15):1433\u201341.","journal-title":"N Engl J Med"},{"issue":"26","key":"4997_CR36","doi-asserted-by":"publisher","first-page":"11775","DOI":"10.1073\/pnas.1004250107","volume":"107","author":"AD Sheftel","year":"2010","unstructured":"Sheftel AD, Stehling O, Pierik AJ, Elsasser HP, Muhlenhoff U, Webert H, et al. Humans possess two mitochondrial ferredoxins, Fdx1 and Fdx2, with distinct roles in steroidogenesis, heme, and Fe\/S cluster biosynthesis. Proc Natl Acad Sci USA. 2010;107(26):11775\u201380.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"25","key":"4997_CR37","doi-asserted-by":"publisher","first-page":"10139","DOI":"10.1073\/pnas.1019441108","volume":"108","author":"N Strushkevich","year":"2011","unstructured":"Strushkevich N, MacKenzie F, Cherkesova T, Grabovec I, Usanov S, Park HW. Structural basis for pregnenolone biosynthesis by the mitochondrial monooxygenase system. Proc Natl Acad Sci USA. 2011;108(25):10139\u201343.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"4997_CR38","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.celrep.2019.07.001","volume":"28","author":"LA Donehower","year":"2019","unstructured":"Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, et al. Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas. Cell Rep. 2019;28(5):1370\u201384.","journal-title":"Cell Rep"},{"issue":"2","key":"4997_CR39","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/ng1070","volume":"33","author":"D Bergamaschi","year":"2003","unstructured":"Bergamaschi D, Samuels Y, O\u2019Neil NJ, Trigiante G, Crook T, Hsieh JK, et al. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet. 2003;33(2):162\u20137.","journal-title":"Nat Genet"},{"issue":"3","key":"4997_CR40","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151\u201372.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"4997_CR41","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/hep.27793","volume":"62","author":"F Heymann","year":"2015","unstructured":"Heymann F, Peusquens J, Ludwig-Portugall I, Kohlhepp M, Ergen C, Niemietz P, et al. Liver inflammation abrogates immunological tolerance induced by Kupffer cells. Hepatology. 2015;62(1):279\u201391.","journal-title":"Hepatology"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-022-04997-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12859-022-04997-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-022-04997-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T10:10:30Z","timestamp":1668593430000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-022-04997-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4997"],"URL":"https:\/\/doi.org\/10.1186\/s12859-022-04997-0","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,16]]},"assertion":[{"value":"25 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"485"}}